To assess the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer, 74 eligible patients were treated. The response rate was not better than those noted in subsequent phase 3 studies of docetaxel-based therapies. Because better-tolerated therapies have since been approved, we cannot recommend further development of this regimen. Introduction: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). Patients and Methods: We enrolled 77 patients who had received no prior chemotherapy for CRPC between 1998 and 2000; a total of 74 subjects were eligible for the study. Each 8-week cycle included paclitaxel 90 mg/m 2 provided intravenously weekly for 6 weeks, followed by 2 weeks off therapy and oral estramustine 280 mg twice daily for 3 days beginning 24 hours before the first dose of paclitaxel. The primary end point was rate of objective or prostate-specific antigen (PSA) response at 16 weeks. A 50% response rate was considered of further interest. Results: Eligible patients received a median of 3 cycles (range, 1-10 cycles). The response rate among patients with measurable disease was 34% (95% confidence interval [CI], 19-52). The PSA response rate was 58% (95% CI, 47-70). Clinical benefit rate was 45% (95% CI, 33-57). The median progression-free survival was 5.9 months (95% CI, 4.4-6.7). The median overall survival was 17.6 months (95% CI, 14.6-20.8). The most common clinical grade 3/4 toxicities were fatigue (14%) and sensory neuropathy (7%). Grade 3/4 hematologic toxicities included lymphopenia (21%) and anemia (9%). There was one toxicity-related death. Quality-of-life scores improved by week 8, but the change was not statistically significant. Conclusion: The combination has activity defined by PSA declines in CRPC but did not meet the protocol-specified end point for efficacy as defined by objective response rate. Since this study was conducted, more effective, better-tolerated regimens have been developed.
Introduction
Although prostate cancer is sensitive to the effects of medical or surgical castration, the disease of most patients will eventually become castration resistant, requiring subsequent treatments. Treatments for metastatic castration-resistant prostate cancer (CRPC) now include secondary hormone therapy, [1] [2] [3] [4] immunotherapy, 5 radiopharmaceuticals, 6 and chemotherapy. Two taxanes, docetaxel 7, 8 and cabazitaxel, 9 are now standard treatments. Estramustine is a nitrogen mustard derivate of estradiol 17b-phosphate. The oral formulation of estramustine was approved by the US Food and Drug Administration in 1981 for the palliative treatment of CRPC. Although the exact mechanism of action is unknown, it has been shown to have both hormonal and nonhormonal effects including inhibition of microtubule function. 10, 11 Estramustine has been studied in combination with the taxanes docetaxel and paclitaxel, as well as with vinblastine. 12 We present the results of ECOG-ACRIN 1898, a multicenter phase 2 study of weekly paclitaxel and estramustine in metastatic CRPC. This regimen was developed to improve on the efficacy and ease of administration of a previous paclitaxel and estramustine combination in which paclitaxel had been provided as a 96-hour intravenous infusion. 13 Phase 1 data of the combination found that daily estramustine had unacceptably toxicity. 14 Our primary objectives were to determine the activity of weekly paclitaxel plus estramustine on prostate-specific antigen (PSA) response, to describe the toxicity of the combination, and to determine this regimen's impact on pain, asthenia, and quality of life.
Methods

Eligibility
Eligible patients were required to be at least 18 years of age and to have histologically proven adenocarcinoma of the prostate with evidence of progressive metastatic disease. Patients with an elevated serum PSA or serum acid phosphatase level as the only evidence of disease were ineligible. Patients with bone metastases only were required to have a PSA level of 20 ng/mL. Patients with soft tissue metastases (eg, pelvic mass, lymph node, liver, or lung) were required to have bidimensionally measurable disease or a PSA level of 20 ng/mL.
Patients had to have prior treatment with bilateral orchiectomy or other primary hormone therapy with evidence of treatment failure. Patients treated with flutamide or nilutamide were required to discontinue these medications at least 4 weeks before registration, and discontinuation of bicalutamide was required at least 6 weeks before registration with continued evidence of progressive disease. Patients who had received prior treatment with chemotherapy or with radioisotope therapies were ineligible. Prior external-beam radiotherapy was allowed if completed at least 4 weeks before study entry.
Other requirements included Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, adequate bone marrow function, defined as white blood cell count 4000/mL or granulocytes 2000/mL and platelet count 1,000,000 mL, and adequate liver function (total bilirubin 1.5 mg/dL, transaminase levels [aspartate aminotransferase, alanine aminotransaminase] 2 times normal), and renal function (creatinine 2 mg/dL or calculated creatinine clearance 50 mL/min) within 4 weeks of study entry.
Patients with a history of venous thromboembolism, carcinomatous meningitis, or brain metastases were excluded. Patients with a history of malignancy were eligible provide they had been treated with curative intent and had been free of disease for the time period considered appropriate for cure of the specific cancer. All patients provided written informed consent according to federal guidelines and those of their local institutional review boards.
Treatment
Each 8-week treatment cycle consisted of paclitaxel administered by 1-hour intravenous infusion at a dose of 90 mg/m 2 each week for 6 weeks, followed by 2 weeks off therapy. As prophylaxis for hypersensitivity reactions, a premedication regimen consisting of dexamethasone, H 2 blockers, and diphenhydramine was administered before each dose of paclitaxel. Estramustine was administered by mouth at a fixed dose of 280 mg twice a day for 3 days beginning 24 hours before the first dose of paclitaxel. This 3-day sequence was repeated each week for 6 weeks and was followed by 2 weeks of rest. Doses of estramustine that were omitted were not to be added on to later doses.
In response to hematologic toxicity, the doses of paclitaxel and estramustine were based on the complete blood count obtained on the day of treatment, with 25% dose reduction of paclitaxel dose if granulocyte count was 1200 to 1999/mL, or platelets were 75,000 to 99,000/mL. For granulocytes < 1200/mL or platelets < 75,000/mL, both paclitaxel and estramustine were held until recovery to minimal levels required for retreatment as noted above. If blood counts were not recovered by day 15 from the last dose, the patient was withdrawn from the study. In response to nonhematologic toxicity, both agents were reduced by 25% for grade 2 toxicity, and for grade 3/4 toxicity, they were held until toxicity resolved to grade 0 to 1, then reduced to 75% of the doses for both. Exceptions for nausea and edema were specified in the protocol.
Patients who had not undergone orchiectomy were required to continue luteinizing hormone releasing hormone therapy for the duration of protocol therapy. Prophylactic use of granulocytecolony stimulating factor or its use for uncomplicated febrile neutropenia was not permitted. Patients were not provided warfarin or other anticoagulants for prophylaxis of venous thromboembolism.
Quality of Life
Before treatment and at weeks 4, 8, 20 , and 24, patients completed the Brief Pain Inventory (BPI) Short Form, the Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) quality-of-life survey, and the Schwartz Cancer Fatigue Scale. Patients were required to complete a pain medication diary during the 48-hour period before each of these assessment times. The primary comparison of interest for the patient-reported outcomes was a comparison of baseline and week 8 assessments.
Toxicity
Toxicities were assessed at every infusion and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 2.0.
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Response
The primary end point was the proportion of patients with objective response or PSA response by 16 weeks. Response was assessed separately for patients with and without measurable disease. For patients without measurable disease, response was defined as a PSA decrease by 50% or greater from baseline measured at 2 successive visits 4 weeks apart. Progressive disease in these patients was defined as an increase in serum PSA above the nadir value achieved by at least 50% for 3 successive measurements at least 4 weeks apart. Patients who did not meet criteria for response or progression for at least 90 days were considered to have stable disease.
For patients with measurable disease, a complete response was the complete disappearance of all clinically detectable malignant disease for at least 4 weeks. Partial response was a decrease of 50% tumor area (defined as multiplication of the longest diameter by the greatest perpendicular diameter) or 50% decrease in the sum of the products of the perpendicular diameters of multiple lesions in the same organ site for at least 4 weeks' duration, with no increase in size of any malignant disease or appearance of new lesions. Disappearance of bone lesions was noted but was not considered to be a response.
Progressive disease was defined as a 25% increase in the area of any malignant lesions > 2 cm 2 or 50% increase in the size of smaller lesions, or the appearance of new lesions. Patients who developed new symptomatic bone lesions were considered to have experienced disease progression. In addition, deterioration in ECOG performance status of 1 level related to malignancy was also considered progression. Stable disease was defined as no complete response, partial response, or progressive disease as defined above for at least 12 weeks.
Statistical Considerations and Study Design
The primary response end point was the proportion of patients who by week 16 experienced reduction in serum PSA of 50%, confirmed by a second measurement 4 weeks later, or who had a partial response or complete response in bidimensionally measurable disease. A 2-stage accrual design was adopted. In the first stage, 15 eligible patients were to be enrolled. If 5 or more responses were observed, the design called for an additional 37 eligible patients to be enrolled. The study with this design had an 8% probability of rejecting the treatment if it was effective ( 50% response rate) and a > 99% probability of rejecting the treatment if it was ineffective ( 20% response rate). If criteria for efficacy were met (20 or more responses among 52 patients), additional patients with measurable disease were to be enrolled to better define the response rate such that the total with measurable disease was 38 patients. No formal protocol specific criteria were established for bone disease.
Progression-free survival was defined as time from study registration until first progression of any applicable type (measurable disease, PSA, or bone) or death, whichever came first. Patients alive without progression were censored at the last date known to be free of progression. For patients who only experienced PSA progression, time to progression was defined as time from registration until the first measurement showing at least 50% increase from the nadir value. Overall survival was defined as time from study registration until death from any cause.
The primary quality-of-life end point was change in FACT-P score at week 8. It was assumed that 70%, or approximately 36 patients, would provide both baseline and 8-week measurements. Assuming that the baseline FACT-P score would be 109 with a standard deviation of 18.6 points, the study had 80% power to detect half a standard deviation, or a 9-point change, from baseline to week 8.
Descriptive statistics were used to characterize patients at study entry. The method of Kaplan and Meier was used to describe progression-free survival and overall survival. The paired t test was used to test for differences in quality of life between baseline and week 8. This study was approved by the institutional review boards at all sites.
Results
Patient and Recruitment Timeline
After the study met its first-stage accrual goal, it was suspended for response assessment on April 29, 1999, and reactivated on June 24, 1999, after the necessary responses were observed. It was suspended again on October 20, 1999, after meeting its accrual goal of 67 patients. After determining that the disease of 20 patients had displayed a response, it was reopened to patients with measurable disease on June 14, 2000. After accruing 11 additional patients with measurable disease, the study was terminated on December 15, 2000.
One patient was registered twice, resulting in 77 unique patients. Of these, 3 patients were ineligible, primarily because of baseline laboratory values that did not meet inclusion criteria. Patients were accrued from 21 ECOG (now ECOG-ACRIN) institutions and affiliates. Pretreatment characteristics of the 74 eligible patients are summarized in Table 1 . Patients were removed from treatment as a result of progressive disease (44.3%), patient request (20.3%), excessive toxicity (14.9%), other complications (2.7%), death without progression (2.7%), and other reasons (12.2%). Table 2 shows toxicities of each type that were considered to be possibly, probably, or definitely related to treatment and were observed in more than 1 patient at grade 3 or higher, or in at least 1 patient at grade 4 or higher. Worst-degree toxicities for each patient are tabulated. Table 2 includes data from all 77 treated patients, regardless of eligibility status. The most common clinical toxicities were fatigue, affecting 14% of patients at grade 3/4, and sensory neuropathy, affecting 7% at grade 3/4. Hematologic toxicities included lymphopenia (21% grade 3/4) and anemia (9%). One patient died after 1 cycle of treatment after experiencing renal failure and pulmonary emboli.
Toxicity
Response
The primary response end point was the proportion of patients who by week 16 achieved reduction in serum PSA of 50%, confirmed by a second measurement 4 weeks later, or who had a partial response or complete response in bidimensionally measurable disease. These 2 end points were assessed separately. Response based on assessment (measurable disease, PSA, or bone disease) is shown in Table 3 .
Measurable Disease. Among the 35 patients who had measurable disease, 12 (34%, 95% exact binomial confidence interval [CI], 19-52) had disease that responded to treatment. PSA Response. Among 73 patients with elevated PSA, 43 (58%, 95% exact binomial CI, 47-70) met the criteria for PSA response. As noted, no formal response criteria was noted for bone lesions. However, 4 of these patients experienced progression in bone.
Clinical Benefit. To construct a consolidated measure of clinical benefit, we considered patients with measurable disease who exhibited an objective response, regardless of PSA status, to have had a response, provided there was no evidence of worsening bone 
Survival and Progression-Free Survival
At the time follow-up ceased (March 2, 2004), 74 patients had died. All patients had experienced disease progression. Median progression-free survival was 5.9 months (95% CI, 4.4-6.7) (Figure 1) .
Overall survival was defined as time from study registration until death from any cause. Median overall survival was 17.6 months (95% CI, 14.6-20.8) (Figure 2) .
Quality of Life, Pain, and Fatigue
Sixty-four patients completed the baseline and 8 week FACT-P surveys. The mean baseline score was 100.4, with a standard deviation of 19.6 points. There was a 4-point improvement in FACT-P score from baseline to 4 weeks, a significant improvement (P ¼ .02). This difference had diminished somewhat by week 8, to a 3-point improvement (P ¼ .18) (Figure 3) . Results are shown in Table 4 .
Seventy-one patients completed the BPI at baseline, and 52 of these patients reported worst pain of 2 of 10 or higher. Forty-three of these 52 patients completed the BPI at 4 weeks. Nineteen (44%) had at least a 2-point decrease on the 10-point pain scale. Five additional patients decreased narcotic dose by at least 50% without increase in pain score. Thus, 59% of patients had either decreased pain or narcotic dose.
Seventy-two and 58 patients completed the Schwartz Cancer Fatigue Scale at baseline and 8 weeks, respectively. The mean score 
Discussion
This multi-institutional phase 2 trial characterizes the activity of paclitaxel provided together with oral estramustine in patients with hormone-refractory prostate cancer. The median progression-free survival and overall survival for this regimen were 5.9 and 17.9 months, respectively. This weekly paclitaxeleestramustine regimen was associated with a low incidence of severe toxicity. As anticipated, fatigue was the most common toxicity, but it was of grade 3 and 4 severity in only 10 and 1 patients, respectively. The 8% incidence of venous thrombosis was similar to the 7% reported in a meta-analysis of 23 estramustine-containing regimens studied in 896 patients. 15 Patient-reported outcomes of fatigue using validated instruments confirmed that fatigue was prevalent but not intrusive for most, even after multiple cycles of treatment. Similarly, patient-reported measures did not demonstrate a decrease of quality of life over time. In addition, treatment with weekly paclitaxel and oral estramustine led to significant pain relief or reduction of narcotic dosage for 59% of patients with narcotic-requiring pain at baseline.
Although these data were collected in a different era of prostate cancer treatment, they are important to summarize and put into context. Fortunately, the clinical landscape for treatment of metastatic CRPC has changed significantly. Docetaxel has been used as first-line chemotherapy since 2004, when 2 studies reported a survival benefit of docetaxel-based chemotherapy compared to mitoxantrone and prednisone. In TAX 327, the experimental arm received either docetaxel provided on a weekly or every-3-week basis in addition to prednisone. 8 In SWOG 9916, the experimental arm received docetaxel 60 mg/m 2 on day 1 every 3 weeks in combination with estramustine (280 mg 3 times per day on days 1-5).
7
Although associated with increased efficacy compared to the mitoxantrone arm, the estramustine-containing arm in SWOG 9916 was also associated with increased toxicity including thromboembolic events and gastrointestinal symptoms. Since the every-3-weeks docetaxel and prednisone arm of TAX 327 had similar efficacy but less toxicity, docetaxeleprednisone has been adopted as a standard of care for men with CRPC. The American Society of Clinical Oncology practice guidelines now advise against the use of estramustine as a result of increased toxicity without improvement in survival or symptom palliation. 16 Along with reports of poor gastrointestinal tolerance, the risk of thromboembolism has been cited to be as high as 12%. 15 Investigators have explored its use in both prospective clinical trials and retrospective studies across a variety of disease states, and for doses both with and without thromboprophylaxis. [17] [18] [19] [20] [21] These studies have yielded mixed results regarding efficacy and toxicity profiles. As a result, there is no clinical setting or dose of estramustine where the clinical benefits have been found to outweigh the risks. This study also highlights the progress made in the design and interpretation of studies of CRPC since this study was developed. As described, PSA and disease measurements were used to characterize response to treatment in E1898. Although the protocol did not include formal criteria for describing bone response, it did note that the development of new symptomatic lesions represented progressive disease. Since then, the Prostate Cancer Working Group (PCWG) has developed formal response criteria for bone metastases using the "2 þ 2 rule" to distinguish tumor progression from tumor flare-up after starting treatment. In addition, Response Evaluation Criteria in Solid Tumors definitions of response and progression in patients with measurable disease have been developed since this study was developed. The PCWG 3 guidelines also include criteria to define progression in small lymph nodes, which is important given the high incidence of lymph node metastases in men with prostate cancer. 22 It is unlikely that our results would have differed significantly if the study were evaluated under newer response criteria; in particular, the bone criteria noted progression if new painful metastases were noted in spite of a declining PSA. Our results were similar to contemporary studies of estramustineetaxaneebased therapy. 17 In summary, we found that paclitaxel and estramustine treatment in patients with CRPC is active but does not provide sufficient clinical benefit. The results of this uncontrolled clinical trial were not better than those noted in later randomized phase 3 studies of docetaxel-based therapies. Because newer therapies with more favorable toxicity profiles have since been approved for CRPC, we cannot recommend the further development of this regimen.
Clinical Practice Points
Estramustine has been shown to have both hormonal and nonhormonal effects, including inhibition of microtubule function. It has been studied in combination with both paclitaxel and docetaxel for CRPC. In this study, the combination of estramustine and paclitaxel did not meet protocol-specified end points for response. Practice guidelines from the American Society of Clinical Oncology practice guidelines advise against the use of estramustine as a result of increased toxicity without improvement in survival or symptom palliation. Since the study was conducted, more effective and bettertolerated regimens for CRPC have been developed. Table 4 Quality 
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